Details for New Drug Application (NDA): 218549
✉ Email this page to a colleague
NDA 218549 describes ZUNVEYL, which is a drug marketed by Alpha Cognition and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the ZUNVEYL profile page.
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this compound. Additional details are available on the benzgalantamine gluconate profile page.
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this compound. Additional details are available on the benzgalantamine gluconate profile page.
Summary for 218549
| Tradename: | ZUNVEYL |
| Applicant: | Alpha Cognition |
| Ingredient: | benzgalantamine gluconate |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 218549
Generic Entry Date for 218549*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 218549
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549 | NDA | Alpha Cognition, Inc. | 84054-005 | 84054-005-60 | 60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-005-60) |
| ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549 | NDA | Alpha Cognition, Inc. | 84054-010 | 84054-010-60 | 60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-010-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Jul 26, 2024 | TE: | RLD: | Yes | |||||
| Patent: | 11,795,176 | Patent Expiration: | Jan 13, 2042 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
| Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||
| Patent: | 9,763,953 | Patent Expiration: | Dec 1, 2026 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Jul 26, 2024 | TE: | RLD: | Yes | |||||
| Patent: | 11,795,176 | Patent Expiration: | Jan 13, 2042 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
| Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||
Complete Access Available with Subscription
